KRISTEN MCCORQUODALE: Open Payments
NPI 1104479104 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,070 in 147 payments from 21 companies in 2025. Trend: 2023 $1,617 · 2024 $2,687 · 2025 $4,070
Food & beverage: $3,898Education: $172
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 13 | $703 |
| Janssen Biotech, Inc. | 21 | $674 |
| Galderma Laboratories, L.P. | 12 | $652 |
| Regeneron Healthcare Solutions, Inc. | 19 | $354 |
| Lilly USA, LLC | 12 | $350 |
| ABBVIE INC. | 13 | $262 |
| GENZYME CORPORATION | 8 | $188 |
| Kerecis Limited | 7 | $175 |
| Organon LLC | 10 | $133 |
| Incyte Corporation | 6 | $111 |
Products named: Bimzelx, TREMFYA, NEMLUVIO, DUPIXENT, Kerecis SurgiClose, TALTZ, RINVOQ, OPZELURA.
Industry payments across TX — which companies pay providers there.
